 "Piramal Enterprises trims loss to Rs 510 crore in March quarter")
Piramal Enterprises’ two business units — financial services and pharma — have posted a consolidated net loss of Rs 510.39 crore in fourth quarter ended March 2021 (Q4FY21) as against consolidated net loss of Rs 1,702.59 crore in the quarter ended March 2020.
For FY21, its consolidated net profit were at Rs 1,412.86 crore as against consolidated profit of Rs 21.34 crore for FY20. The board has recommended a dividend of Rs 33 per share for FY21, subject to shareholders’ approval.
The total dividend payout on this account would be Rs 788 crore. Its stock closed flat (0.17 per cent) at Rs 1,694.6 per share on the BSE.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%